Pfizer and Zai Lab announced a strategic collaboration for the novel antibacterial drug XACDURO (sulbactam-durlobactam) in mainland China. Under this agreement, Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO in the region.
XACDURO is the only antimicrobial agent specifically developed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB), a critical priority pathogen identified by the World Health Organization. It has been approved in both the United States and mainland China for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible CRAB isolates.
This collaboration aims to accelerate patient access to this important therapy in mainland China, where Acinetobacter baumannii was the leading cause of death attributable to antimicrobial resistance in 2019. The agreement leverages Pfizer's established commercial infrastructure in the anti-infective therapeutic area, with the collaboration period extending through November 2028.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.